Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0044-1786162
Original Article

Profile and Outcomes of COVID-19 Infection in Pediatric Patients with and without Cancer: A Case–Control Study

Puneet Kaur Sahi
1   Department of Pediatrics, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India
,
Varun Kumar 
1   Department of Pediatrics, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India
,
Arpita Gupta
1   Department of Pediatrics, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India
,
Mampy Das
1   Department of Pediatrics, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India
,
Priyanka Meena
1   Department of Pediatrics, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India
,
Divyanshi Divyanshi
1   Department of Pediatrics, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objectives Pediatric patients with cancer are considered a vulnerable population to the ill effects of coronavirus disease 2019 (COVID-19). We hereby studied the difference between clinical characteristics, lab parameters, and outcomes of COVID-19 among children suffering from cancer and those without cancer. We also analyzed risk factors for the occurrence of moderate-to-severe COVID-19 disease in pediatric cancer patients.

Materials and Methods This retrospective case–control study was carried out using the medical record review method over 6 months in a tertiary-care center in India. All patients below 18 years of age, with reverse-transcriptase polymerase chain reaction (RTPCR) confirmed COVID-19, were screened for enrolment. Patients were split into two groups: Group A comprised of patients with cancer, while group B consisted of patients without any underlying comorbidity. Patients with other comorbidity except cancer and inadequately recorded case sheets were excluded. Details regarding demography, clinical features, investigations, treatment, and outcomes were recorded.

Statistical Analysis Microsoft Excel and Statistical Package for the Social Sciences (SPSS) software, version 25 was used for data analysis. A p-value less than 0.05 was considered significant.

Results Two-hundred-five pediatric inpatients with RTPCR-established COVID-19 infection were screened and final analyses were performed on 97 patients, of which 31 children were classified into group A and 66 into group B. Median age of enrolled children was 5 years with 58.8% males. The prevalence of cancer as a comorbidity in pediatric inpatients with COVID-19 was 15%. Fifty-five percent of cancer patients had hematological malignancies, while 45% had solid tumors. Fever (p = 0.001) and gastrointestinal manifestations (p = 0.0001) were significantly less common among pediatric cancer patients. Children with cancer had significantly more leukopenia (p = 0.003), neutropenia (p = 0.003), and lymphopenia (p = 0.005). The case fatality rate was higher in children with cancer (3.2%) as compared to noncancer patients (1.5%, p = 1.0). Few risk factors for moderate-to-severe COVID-19 among children with cancer included age less than 2 years (p = 0.06), undernutrition (p = 0.33), advanced stage of cancer (p = 0.49), and presence of coinfection (p = 0.35)

Conclusion Cancer is a significant comorbidity among pediatric COVID-19 patients. While children with cancer have less severe COVID-19, their case fatality rate is higher than those without cancer. Younger age, undernutrition, advanced stage of cancer, and presence of coinfections may predispose to the development of moderate-to-severe COVID-19 among pediatric cancer patients.

Keywords

SARS-CoV-2 - pediatric cancer - hematological malignancy - risk factors - severe disease - solid tumors

Authors' Contributions

P.K.S. conceptualized, drafted, and critically appraised the manuscript.


V.K. helped in data collection, reviewed literature, and drafted the manuscript. A.G. conceptualized, reviewed literature, and critically appraised the manuscript.


M.D., P.M., and Divyanshi helped in data collection and review of literature.


Financial Support and Sponsorship

None.


Ethical Approval

Ethical approval was taken from the Institute Ethics Committee prior to commencement of this work.


Patient Consent

None declared.




Publication History

Article published online:
13 May 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hazarika M, Reddy RT, Rai AK. et al. COVID-19 prevalence and survival outcome in pediatric cancer patients undergoing chemotherapy: a study from tertiary cancer center of North-East India. Asian Pac J Cancer Care. 2022; 7 (03) 475-480
    CrossrefGoogle Scholar
  • 2 Kompaniyets L, Agathis NT, Nelson JM. et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021; 4 (06) e2111182
    CrossrefPubMedGoogle Scholar
  • 3 Raj R, Uppuluri R, Parambil B. et al. Outcomes of COVID-19 in children with cancer – report from the Indian Pediatric Oncology Group (InPOG) COVID-19 registry in India. Pediatric Hematol Oncology J 2022; 7 (02) 34-37
    CrossrefGoogle Scholar
  • 4 Pocket book of COVID-19. Ministry of health and family welfare. Government of India. Published March 27, 2020. Accessed April 3, 2024 at: https://www.mohfw.gov.in/pdf/3Pocketbookof5_Covid19_27March.pdf
    Google Scholar
  • 5 Updated Clinical Management Protocol for COVID-19. Ministry of Health and Family Welfare. Government of India. Published July 3, 2020. Accessed April 3, 2024 at: https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf
    Google Scholar
  • 6 COVID-19 Management For 1 Month - 19 Years Old: Statement by Indian Academy of Pediatrics (April 2021). Last accessed 18 Sept 21. Accessed April 3, 2024 at: https://iapindia.org/pdf/yOQBzDmtbU4R05M_IAP%20Covid%2019%20managementGuidelines%20for%20Pediatrician%20V1.1%20Apr%2027_2021%20(2).pdf
    Google Scholar
  • 7 Stanley F. Reference intervals for laboratory tests and procedures. In: Kliegman RM, Geme JW, Blum NJ. et al., eds. Nelson Textbook of Pediatrics, 21st ed. Philadelphia: Elsevier; 2019: 2466 e6-e12
    Google Scholar
  • 8 Sitanggang JS, Siregar KB, Sitanggang HH, Sprinse Vinolina N. Prevalence of cancer as a comorbid in COVID-19 patients and their characteristics: a meta-analysis study. F1000 Res 2021; 10: 975
    CrossrefGoogle Scholar
  • 9 Zarifkar P, Kamath A, Robinson C. et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol) 2021; 33 (03) e180-e191
    CrossrefPubMedGoogle Scholar
  • 10 Singh P, Attri K, Mahto D. et al. Clinical profile of COVID-19 illness in children-experience from a tertiary care hospital. Indian J Pediatr 2022; 89 (01) 45-51
    CrossrefPubMedGoogle Scholar
  • 11 Schuster FR, Simon A, Laws HJ. et al. [Viral infections in pediatric cancer patients]. Klin Padiatr 2005; 217 (Suppl. 01) S67-S84
    PubMedGoogle Scholar
  • 12 COVID-19 and Childhood Cancer Registry [Internet]. St. Jude Global. [cited 2023 June 14]. Accessed April 3, 2024 at: https://global.stjude.org/en-us/global-covid-19-observatory-and-resource-center-forchildhood-cancer/registry.Html
    Google Scholar
  • 13 Lee LYW, Cazier JB, Starkey T. et al; UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020; 21 (10) 1309-1316 [published correction appears in Lancet Oncol. 2020 Sep 3;]
    CrossrefPubMedGoogle Scholar
  • 14 Abdul-Jawad S, Baù L, Alaguthurai T. et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell 2021; 39 (02) 257-275.e6
    CrossrefPubMedGoogle Scholar
  • 15 Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood 2022; 140 (03) 236-252
    CrossrefPubMedGoogle Scholar
  • 16 Maia C, Martín-Sánchez E, Garcés JJ. et al. Immunologic characterization of COVID-19 patients with hematological cancer. Haematologica 2020; 106 (05) 1457-1460
    CrossrefPubMedGoogle Scholar
  • 17 Kalicińska E, Szymczak D, Andrasiak I. et al. Lymphocyte subsets in haematological patients with COVID-19: multicentre prospective study. Transl Oncol 2021; 14 (01) 100943
    CrossrefPubMedGoogle Scholar
  • 18 Bilich T, Roerden M, Maringer Y. et al. Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer. Cancer Discov 2021; 11 (08) 1982-1995
    CrossrefPubMedGoogle Scholar
  • 19 Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020; 53: 25-32
    CrossrefPubMedGoogle Scholar
  • 20 Wang JG, Cui HR, Tang HB, Deng XL. Gastrointestinal symptoms and fecal nucleic acid testing of children with 2019 coronavirus disease: a systematic review and meta-analysis. Sci Rep 2020; 10 (01) 17846
    CrossrefPubMedGoogle Scholar
  • 21 Patel KP, Patel PA, Vunnam RR. et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol 2020; 128: 104386
    CrossrefPubMedGoogle Scholar
  • 22 Sougiannis AT, VanderVeen BN, Davis JM, Fan D, Murphy EA. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol 2021; 320 (05) G712-G719
    CrossrefPubMedGoogle Scholar
  • 23 Ma X, Liu S, Chen L, Zhuang L, Zhang J, Xin Y. The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: a meta-analysis and systematic review. J Med Virol 2021; 93 (01) 234-240
    CrossrefPubMedGoogle Scholar
  • 24 Schlage S, Lehrnbecher T, Berner R, Simon A, Toepfner N. SARS-CoV-2 in pediatric cancer: a systematic review. Eur J Pediatr 2022; 181 (04) 1413-1427
    CrossrefPubMedGoogle Scholar
  • 25 Miyashita H, Mikami T, Chopra N. et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020; 31 (08) 1088-1089
    CrossrefPubMedGoogle Scholar
  • 26 Robilotti EV, Babady NE, Mead PA. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020; 26 (08) 1218-1223
    CrossrefPubMedGoogle Scholar
  • 27 Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol 2022; 8 (01) 69-78
    CrossrefPubMedGoogle Scholar
  • 28 Chowdhoury SR, Biswas HS, Raut S. et al. Pediatric oncology patients and COVID-19: an experience from the tertiary COVID care facility in Eastern India: a prospective observational study. Indian J Med Paediatr Oncol 2021; 42: 130-134
    Article in Thieme ConnectGoogle Scholar
  • 29 Harwood R, Yan H, Talawila Da Camara N. et al. Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: a systematic review and individual patient meta-analysis. EClinicalMedicine 2022; 44: 101287
    CrossrefPubMedGoogle Scholar
  • 30 Zhu PH, Mhango SN, Vinnakota A, Mansour M, Coss-Bu JA. Effects of COVID-19 pandemic on nutritional status, feeding practices, and access to food among infants and children in lower and middle-income countries: a narrative review. Curr Trop Med Rep 2022; 9 (04) 197-206
    CrossrefPubMedGoogle Scholar
  • 31 Raychaudhuri D, Sarkar M, Roy A. et al. COVID-19 and coinfection in children: the Indian perspectives. J Trop Pediatr 2021; 67 (04) fmab073
    CrossrefPubMedGoogle Scholar